KromaTiD Announces Third U.S. Patent and New Proprietary Capabilities

KromaTiD Announces Third U.S. Patent and New Proprietary Capabilities Fort Collins, Colorado September 21, 2015:  With the issuance of its third U.S. patent (#9,090,935 B2), KromaTiD is pleased to announce an expansion of its full genome screening platform to include a new set of unique methods for understanding the structure of novel disease causing mutations.